Phase I trials

Compound Type of drug Tumour type
BI 853520 FAK inhibitor Solid tumours (advanced and/or metastatic cancer)
BI 860585 mTOR (mTORC1/mTORC2) inhibitor Solid tumours (advanced or metastatic cancer)
BI 836880 VEGF/Ang 2 inhibitor Solid tumours (advanced)
BI 836858 CD33 monoclonal antibody Acute myeloid leukaemia


This is an investigational compound and has not yet been fully approved. Its safety and efficacy has not yet been fully established.

FAK, focal adhersion kinase; mTOR, mammalian target of rapamycin; VEGF, vascular endothelial growth factor.

Last updated August 2016.